Research Article

A view on Financial Position and Performance of Select Pharmaceutical Industries in India

1. A. Jalaludeen

Ph.D -Research Scholar at Jamal Mohamed College &
Assistant Professor of Commerce
Directorate of Distance Education
SRM Institute of Science and Technology,
Chennai.
Mail Id: jallujalal79@yahoo.com

2.Dr. M. Marimuthu

Assistant Professor,
Department of Commerce,
Jamal Mohamed College, Trichy

Abstract

The Indian Pharmaceutical part is exceptionally divided with in excess of 20,000 enlisted units. It has exhausted definitely over the most recent two decades. The Pharmaceutical Industry in India meets around 70 of the nation's interest for mass medications, tranquilize intermediates, pharmaceutical detailing, synthetic compounds, tablets, orals and injectibles. There are roughly 250 huge units and around 8000 little scope units, which structure the center of the Pharmaceutical Industry in India (counting 5 focal open segment units)Looking ahead, the overall pharma showcase is evaluated to dramatically increase to $1.3 billion continuously 2020.The Indian Pharmaceutical Industry is growing definitely consistently. Thus an endeavor has been made to break down the gainfulness position of the business with the assistance of mean, standard deviation, coefficient of variety. The expansion in benefit won't only yield more prominent effectiveness yet additionally improve money related execution in future.

Keywords: Pharmaceutical, Profitability, Financial Performance

1. Preamble

The Indian Pharmaceutical Industry today is in the front position of India's science based enterprises with wide extending abilities in the perplexing field of medication assembling and innovation. It positions exceptionally high in the third world, as far as innovation, quality and scope of medications made. From basic cerebral pain pills to advanced anti-infection agents and complex cardiovascular mixes, pretty much every sort of medication is currently made indigenously assuming a key job in advancing and continuing improvement in the fundamental field of drugs.

Universal organizations related with this part have animated, helped and led this dynamic improvement in the previous 53 years and assisted with putting India on the pharmaceutical guide of the world. The Indian Pharmaceutical segment is profoundly divided with in excess of 20,000 enlisted units. It

has extended definitely over the most recent two decades. The main 250 Pharmaceutical Companies control 70 percent of the market with showcase pioneer holding about 7 percent of the piece of the overall industry. It is an amazingly divided market with serious value rivalry and government value control.

The Pharmaceutical Industry in India meets around 70 percent of the nation's interest for mass medications, sedate intermediates, pharmaceutical details, synthetic substances, tablets, containers, orals and injectibles. There are around 250 enormous units and around 8000 Small Scale Units, which structure the center of the Pharmaceutical Industry in India (counting 5 Central Public Sector Units). These units produce the total scope of pharmaceutical plans, i.e., prescriptions prepared for utilization by patients and around 350 mass medications, i.e., synthetic compounds having remedial worth and utilized for creation of pharmaceutical details.

1.1. Rationale of the Study

The advancement of businesses relies upon a few factors, for example, money work force, innovation, nature of the item and advertising. Out of these, monetary and working angles accept a noteworthy job in deciding the development of businesses. The entirety of the organization's activities basically influence its requirement for money. The vast majority of the information covering operational regions are anyway outside the immediate obligation of the money related official. Except if the top administration acknowledges the estimation of a decent money related and working examination, there will be proceeding with issues for the monetary officials to discover the benefit position of the worry.

1.2. Aims of the Study

1. To break down the profitability position of Select Pharmaceutical Companies in India.

2. To analysing the variables impacting the Profitability of chosen Pharmaceutical Companies in India.

3. To offer discoveries and Recommendation and Conclusion.

1.3. Scope of the Study

The present examination targets surveying the gainfulness position of Pharmaceutical Industry in India. The examination could help the organization just as the speculators to comprehend its monetary proficiency. It plans to assist the administration with finding out its budgetary issues at present and the Specific regions in the business, which may require some exertion for increasingly viable and proficient usage of its assets.

2. Review of Past Studies

M. Parveen and O. M. Haja Mohideen (2014) found that each venture at whatever point huge, medium or little needs money to carry on its activities and to accomplish its objective. This examination is to give an understanding into idea of money related execution utilizing five influence investigation comprises of Inventory turnover proportion, Debtors turnover proportion, Creditors turnover proportion, Total resource turnover proportion and Gross overall revenue. The essential goal is to decide the budgetary presentation of Cipla pharmaceutical organization utilizing five force examinations. The optional goals are to look at the connection between Inventory turnover, Debtors turnover, Creditors turnover and Total resource turnover with Gross overall revenue.

Bimal Jaisawal and Namita Srivastava (2014) considered that the Indian pharmaceutical industry is growing around the world. For certain years now, it has been profiting by the specific elements of the

A view on Financial Position and Performance of Select Pharmaceutical Industries in India

Asian economies as the two buyers and makers. A yearly development rate is great. India is right now perceived as a top notch, minimal effort talented maker of pharmaceuticals. It is considered not to be as an assembling base for APIs and definitions, yet in addition as a rising center for biotechnology, bioinformatics, contract examine, clinical datamanagement and clinical preliminaries. Up until 2015, India anticipates that pharmaceutical deals should ascend by 8% p.a. to simply under EUR 20 bn, contrasted and an expansion of 6% on the planet overall.

3. Research Methodology

➢ **Sources of Date**

Secondary data were collected from annual report of the sample company and used for analysis.

➢ **Period of Study**

This research work covered a period of 5 years from financial year 2014 to 2018.

➢ **Tools Used**

Proportion investigation is a method embraced to examination and decipher general fiscal reports to survey the benefit position Further an extensive investigation is conveyed by applying measurable systems specifically mean, standard deviation, co-effective of change.

➢ **Sample Size**

The information for this investigation is chosen dependent on comfort inspecting technique. Among the organizations recorded with significant stock trade of India to be specific, Bombay Stock Exchange and National Stock Exchange of India, 5 organizations with reliable money related information are chosen.

Coming up next are the chosen Pharmaceutical organizations of this investigation

1. **Sun Pharma Industries**
2. **Aurobindo**
3. **Dr.Reddy"s Laboratories Ltd**
4. **Lupin**
5. **Cadila Health Care**

4. Analysis and Interpretation of Data

1. **Gross Profit Ratio**
2. **Net Profit Ratio**
3. **Operating Profit Ratio**
4. **Return on capital employed**

Table No.1- Gross Profit Ratio

Year	Sun Pharma	Aurobindo	Dr.Reddys	Lupin	Cadila
2014-2015	34.32	28.19	19.97	19.23	25.76
2015-2016	42.99	18.48	16.82	21.56	26.87
2016-2017	46.35	19.23	15.79	13.21	21.91
2017-2018	38.32	20.49	13.8	10.23	19.23
2018-2019	33.69	18.4	20.43	23.11	18.24
Avg	39.134	20.958	17.362	17.468	22.402
SD	4.91	3.69	2.52	4.01	3.43

Var	24.08	13.64	6.33	24.44	11.77

It shows the gross benefit proportion of chosen Pharmaceutical Companies in India from 2014-2015 to 2018-2019. This gross benefit proportion shows a fluctuating pattern during the investigation time frame. The Sun Pharma has the most noteworthy mean estimation of 39.13and the Dr.Reddys has the least mean estimation of 17.36. The Sun Pharma has the best standard deviation of gross benefit proportion of 4.91. The Cadila with most minimal standard deviation of gross benefit proportion of 3.43. The Lupin has the most noteworthy coefficient change of gross benefit proportion of 24.44 percent. The Lupin has the most minimal coefficient fluctuation of gross benefit proportion of 11.77 percent and it is discovered that there is a consistency in net benefit proportion than the other Pharmaceutical Companies.

Table No.2- Net Profit Ratio

Year	Sun Pharma	Aurobindo	Dr.Reddys	Lupin	Cadila
2014-2015	18.54	19.23	14.29	16.34	19.34
2015-2016	20.67	20.49	12.41	18.34	17.65
2016-2017	28.98	15.79	11.28	9.43	14.98
2017-2018	35.23	13.8	36.23	-8.93	14.23
2018-2019	33.81	13.32	18.34	32.4	17.23
Avg	27.446	16.526	18.51	13.516	16.686
SD	6.76	2.87	9.18	13.48	1.86
Var	45.74	8.26	84.26	181.67	3.44

The table shows that the net profit ratio of chosen Pharmaceutical Companies in India from 2014-2015 to 2018-2019. The net profit ratio shows the fluctuating pattern during the examination time frame. The Sun Pharma has the most elevated mean estimation of 27.446 and the Lupin has the least mean estimation of 13.51 .The Lupin has the high standard deviation of net benefit proportion of 13.48. The Cadila with most reduced standard deviation of net benefit proportion of 1.86 and it is seen as steady in net benefit proportion. The Dr. Reddy has the most elevated co-productive fluctuation of net benefit proportion of 84.26 percent.The Cadila has the least co-proficient difference of net benefit proportion of 3.44 percent and it is discovered that there is a consistency in net benefit proportion than the other Pharmaceutical Companies.

Table No.3- Operating Profit Ratio

Year	Sun Pharma	Aurobindo	Dr.Reddys	Lupin	Cadila
2014-2015	31.07	24.34	21.54	22.34	30.32
2015-2016	45.64	22.87	16.34	27.89	26.23
2016-2017	46.76	24.54	18.93	15.07	22.12
2017-2018	38.34	26.43	23.45	13.5	24.56
2018-2019	31.87	22.33	22.87	17.34	22.31
Avg	38.736	24.102	20.626	19.228	25.108
SD	6.60	1.44	2.65	5.26	3.02
Var	43.62	2.07	7.02	27.68	9.10

The table depict that the operating profit ratio of select Pharmaceutical Companies in India from 2014-2015 to 2018-2019. The operating profit shows the fluctuating pattern during the examination time frame. The Sun Pharma has the most noteworthy mean estimation of 38.73and the Lupin has the least mean estimation of 19.22.The Sun Pharma has the high standard deviation of operating profit proportion of 6.60. The Aurobindo with most minimal standard deviation of working benefit proportion of 1.44 and it is seen as steady in working benefit proportion. The Sun Pharma has the most noteworthy co-productive change of working benefit proportion of 43.62 percent. The Aurobindo has the least co-effective difference of working benefit proportion of 2.07 percent and it is discovered that there is a consistency in operating profit ratio than the other Pharmaceutical Companies.

Table No.4- Return on Capital Employed Ratio

Year	Sun Pharma	Aurobindo	Dr.Reddys	Lupin	Cadila
2014-2015	13.5	24.34	27.89	22.34	30.32
2015-2016	17.34	22.87	15.07	27.89	46.76
2016-2017	16.34	31.07	18.93	15.07	38.34
2017-2018	18.93	45.64	23.45	13.5	31.87
2018-2019	31.87	22.33	22.87	17.34	22.31
Avg	19.596	29.25	21.642	19.228	33.92
SD	6.39	8.77	4.34	5.26	8.20
Var	40.79	76.93	18.87	27.68	67.27

The table indicates that the Return on capital employed of select Pharmaceutical Companies in India from 2014-2015 to 2018-2019. The Return capital employed shows the fluctuating pattern during the investigation time frame. The cadila has the most noteworthy mean estimation of 33.92 and the Lupin has the least mean estimation of 19.22. .The Aurobindo has the highest standard deviation of profit for capital utilized of 8.77. The Dr.Reddys with most reduced standard deviation of profit for capital utilized of 4.34 and it is seen as steady consequently on capital utilized. The Aurobindo has the most noteworthy co-effective variance of profit for capital utilized of 76.93 percent. The Lupin has the least co-proficient change of profit for capital utilized of 18.87 percent and it is discovered that there is a consistency consequently on capital utilized than the other Pharmaceutical Companies

5. Findings, Recommendations and Conclusion

The Sun Pharma has the most noteworthy mean estimation of 39.13and the Dr.Reddys has the least mean estimation of 17.36. The Sun Pharma has the best standard deviation of gross benefit proportion of 4.91. The Sun Pharma has the most elevated mean estimation of 27.446 and the Lupin has the least mean estimation of 13.51 .The Lupin has the high standard deviation of net benefit proportion of 13.48. The Aurobindo has the most noteworthy co-effective variance of profit for capital utilized of 76.93 percent. The Lupin has the least co-proficient change of profit for capital utilized of 18.87 percent and it is discovered that there is a consistency consequently on capital utilized than the other Pharmaceutical Companies.

The organizations should use an inventive innovation and it might expand the item go. This will expand the fare deals. The outcome will be expanding the outside trade profit. The organizations may focus on their expense of creation, interest in fixed resources and their business turnover to improve their

gainfulness. The monetary wellbeing assumes a noteworthy job in the fruitful administration of an organization. The examination for all intents and purposes uncovers that gross benefit proportion, working proportion, return on value capitaland income pershare, have noteworthy impact on the net benefit proportion of the chose pharmaceutical organizations during the investigation time frame. Be that as it may, gainfulness of the chose pharmaceutical organizations in India during the investigation time frame is good. During the time of study there were a couple good and bad times in the gainfulness however it didn't influence the activities of the organization as it were. On the off chance that the Pharmaceutical Industry needs to perform well, it needs to contribute progressively capital and needs to accomplish more deals, at exactly that point it will improve its presentation level.

6.References

1.   Agarwwal,M.P., Analysis of Financial Statements, National Publishing House, New Delhi,1981,p.5.
2.   Batty, Management Accounting, McDonald and Evans Ltd., 1970, p.413
3.   Amalendu Bhunia(2010),” Financial Performance of Indian Pharmaceutical Industry A Case Study”. Asian Journal Of Management Research, ISSN 2229 – 3795, PP:427-451.
4.   V.Vijayalakshmia and M.Srividyab (2014),”A Study On Financial Performance Of Pharmaceutical Industry In India” Journal of Management and Science, ISSN: 2249-1260, Vol.4. No.3.
5.   Enekwe, Chinedu Innocent Agu, Charles Ikechukwu and Eziedo Kenneth Nnagbogu (2014),” The Effect of Financial Leverage on Financial Performance: Evidence of Quoted Pharmaceutical Companies in Nigeria”. IOSR Journal of Economics and Finance (IOSR-JEF), e-ISSN: 2321-5933, PP 17-25 .